Acute exacerbations in idiopathic pulmonary fibrosis [1]

Annals of Internal Medicine

Volumn 144, Issue 3, 2006, Pages 218-

  Crowley, Seamus P ^a   Kelly, Peter ^a   Egan, Jim J ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; GAMMA INTERFERON;

CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; FIBROSING ALVEOLITIS; HUMAN; LETTER; LUNG FUNCTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; LUNG FIBROSIS; NOTE; PATHOPHYSIOLOGY;

HUMANS; INTERFERON TYPE II; PULMONARY FIBROSIS;

EID: 33644865072     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-144-3-200602070-00014     Document Type: Letter

References (4)

1. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142:963-7.
2. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125-33.
3. Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification [Editorial]. Thorax. 2005;60:270-3.
4. Honore I, Nunes H, Groussard O, Kambouchner M, Chambellan A, Aubier M, et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med. 2003;167:953-7.